Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label,2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structure for [14C]-AQX-1125 in Healthy Subjects

NCT03185195 is registered in ClinicalTrials.gov with Aquinox Pharmaceuticals (Canada) Inc. as lead sponsor.

NCT NCT03185195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03185195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label,2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structure for [14C]-AQX-1125 in Healthy Subjects
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 22, 2016
Completion date
January 4, 2017
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer